Clinical-stage biotechnology company developing patient-centered cell therapies for oncology and autoimmune diseases, with a focus on CAR-based treatments for hematological and solid tumors
Clinical-stage biotechnology company developing patient-centered cell therapies for oncology and autoimmune diseases, with a focus on CAR-based treatments for hematological and solid tumors. Its pipeline includes clinical and preclinical programs, including off-the-shelf CAR-NK and BiTE approaches. The company was established in Cambridge, Massachusetts, in 2019 and completed a GMP facility in Shanghai in 2020.